Intrahepatic cholestasis in common chronic liver diseases

European Journal of Clinical Investigation

Volumn 43, Issue 10, 2013, Pages 1069-1083

  Jüngst, Christoph ^a   Berg, Thomas ^b   Cheng, Jun ^c   Green, Richard M ^d   Jia, Jidong ^e   Mason, Andrew L ^f   Lammert, Frank ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d NORTHWESTERN UNIVERSITY   (United States)

^e CAPITAL MEDICAL UNIVERSITY   (China)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Alcoholic liver disease; Bile; Drug induced cholestasis; Fatty liver disease; Viral hepatitis

Indexed keywords

AJMALINE; AMOXICILLIN PLUS CLAVULANIC ACID; CARBAMAZEPINE; CASCARA SAGRADA; CHAPARRAL; CHLORPROMAZINE; COTRIMOXAZOLE; CYAMEMAZINE; ERYTHROMYCIN; ERYTHROMYCIN DERIVATIVE; FLUCLOXACILLIN; HALOPERIDOL; HERBACEOUS AGENT; IBUPROFEN; ORAL CONTRACEPTIVE AGENT; ORGANOARSENIC DERIVATIVE; PHENOTHIAZINE DERIVATIVE; SULPIRIDE; TERBINAFINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ALCOHOL LIVER DISEASE; BOOK; CHOLESTASIS; CHRONIC HEPATITIS; CHRONIC HEPATITIS B; CHRONIC INTRAHEPATIC CHOLESTASIS; CHRONIC LIVER DISEASE; CHRONIC VIRAL HEPATITIS; DISEASE COURSE; END STAGE LIVER DISEASE; GENETIC VARIABILITY; GRANULOMATOUS LIVER DISEASE; HEPATITIS B; HEPATITIS C; HUMAN; INTRAHEPATIC CHOLESTASIS; LITERATURE; LIVER DISEASE; MEDLINE; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; VIRUS HEPATITIS;

ALCOHOLIC LIVER DISEASE; BILE; DRUG-INDUCED CHOLESTASIS; FATTY LIVER DISEASE; VIRAL HEPATITIS;

CHOLESTASIS, INTRAHEPATIC; CHRONIC DISEASE; FATTY LIVER; GRANULOMA; HEPATITIS; HEPATITIS, VIRAL, HUMAN; HUMANS; LIVER DISEASES, ALCOHOLIC;

EID: 84884699840     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12128     Document Type: Review

References (124)

1. Wagner M, Zollner G, Trauner M. New molecular insights into the mechanisms of cholestasis. J Hepatol 2009;51:565-80.
2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009;51:237-67.
3. Stickel F, Seitz HK. Alcoholic steatohepatitis. Best Pract Res Clin Gastroenterol 2010;24:683-93.
4. European Association for the Study of the Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012;57:399-420.
5. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011;141:1572-85.
6. Morgan MY, Sherlock S, Scheuer PJ. Acute cholestasis, hepatic failure, and fatty liver in the alcoholic. Scand J Gastroenterol 1978;13:299-303.
7. Popper H, Szanto PB. Intrahepatic cholestasis (cholangiolitis). Gastroenterology 1956;31:683-99; discussion, 99-700.
8. Tung BY, Carithers RL Jr. Cholestasis and alcoholic liver disease. Clin Liver Dis 1999;3:585-601.
9. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 1998;339:1217-27.
10. Joseph RA, Shepard BD, Kannarkat GT, Rutledge TM, Tuma DJ, Tuma PL. Microtubule acetylation and stability may explain alcohol-induced alterations in hepatic protein trafficking. Hepatology 2008;47:1745-53.
11. Trinchet JC, Gerhardt MF, Balkau B, Munz C, Poupon RE. Serum bile acids and cholestasis in alcoholic hepatitis. Relationship with usual liver tests and histological features. J Hepatol 1994;21:235-40.
12. Nissenbaum M, Chedid A, Mendenhall C, Gartside P. Prognostic significance of cholestatic alcoholic hepatitis. VA Cooperative Study Group #119. Dig Dis Sci 1990;35:891-6.
13. Kosters A, Karpen SJ. The role of inflammation in cholestasis: clinical and basic aspects. Semin Liver Dis 2010;30:186-94.
14. Altamirano J, Bataller R. Alcoholic liver disease: pathogenesis and new targets for therapy. Nat Rev Gastroenterol Hepatol 2011;8: 491-501.
15. Zollner G, Fickert P, Zenz R, Fuchsbichler A, Stumptner C, Kenner L et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 2001;33:633-46.
16. Sancho-Bru P, Altamirano J, Rodrigo-Torres D, Coll M, Millan C, Jose Lozano J et al. Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis. Hepatology 2012;55:1931-41.
17. Chedid A, Mendenhall CL, Gartside P, French SW, Chen T, Rabin L. Prognostic factors in alcoholic liver disease. VA Cooperative Study Group. Am J Gastroenterol 1991;86:210-6.
18. Sorensen TI, Orholm M, Bentsen KD, Hoybye G, Eghoje K, Christoffersen P. Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis. Lancet 1984;2:241-4.
19. Ballard H, Bernstein M, Farrar JT. Fatty liver presenting as obstructive jaundice. Am J Med 1961;30:196-201.
20. Zieve L. Jaundice, hyperlipemia and hemolytic anemia: a heretofore unrecognized syndrome associated with alcoholic fatty liver and cirrhosis. Ann Intern Med 1958;48:471-96.
21. Melrose WD, Bell PA, Jupe DM, Baikie MJ. Alcohol-associated haemolysis in Zieve's syndrome: a clinical and laboratory study of five cases. Clin Lab Haematol 1990;12:159-67.
22. Kunz F, Stummvoll W. The significance of plasma phospholipids in Zieve syndrome. Blut 1970;21:210-26.
23. Shinozawa S, Araki Y, Utsumi K. Inhibitory effect of cholesterol on changes in membrane permeability and potential induced with lysolecithin in red blood cells (author's transl). Nihon Yakurigaku Zasshi 1978;74:297-302.
24. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009;360:2758-69.
25. Phillips GB, Davidson CS. Acute hepatic insufficiency of the chronic alcoholic; clinical and pathological study. AMA Arch Intern Med 1954;94:585-603.
26. Phillips GB, Davidson CS. Liver disease of the chronic alcoholic simulating extrahepatic biliary obstruction. Gastroenterology 1957;33:236-44.
27. Mathurin P, Duchatelle V, Ramond MJ, Degott C, Bedossa P, Erlinger S et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 1996;110:1847-53.
28. Spahr L, Rubbia-Brandt L, Genevay M, Hadengue A, Giostra E. Early liver biopsy, intraparenchymal cholestasis, and prognosis in patients with alcoholic steatohepatitis. BMC Gastroenterol 2011;11:115.
29. Glover SC, McPhie JL, Brunt PW. Cholestasis in acute alcoholic liver disease. Lancet 1977;2:1305-7.
30. Afshani P, Littenberg GD, Wollman J, Kaplowitz N. Significance of microscopic cholangitis in alcoholic liver disease. Gastroenterology 1978;75:1045-50.
31. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-8.
32. Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 2010;24:695-708.
33. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-9.
34. Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 2010;16:5286-96.
35. Hübscher SG. Histological assessment of non-alcoholic fatty liver disease. Histopathology 2006;49:450-65.
36. Sorrentino P, Tarantino G, Perrella A, Micheli P, Perrella O, Conca P. A clinical-morphological study on cholestatic presentation of nonalcoholic fatty liver disease. Dig Dis Sci 2005;50:1130-5.
37. Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011;54:1208-16.
38. Aranha MM, Cortez-Pinto H, Costa A, da Silva IB, Camilo ME, de Moura MC et al. Bile acid levels are increased in the liver of patients with steatohepatitis. Eur J Gastroenterol Hepatol 2008;20:519-25.
39. Bechmann LP, Kocabayoglu P, Sowa JP, Sydor S, Best J, Schlattjan M et al. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology 2013;57:1394-406.
40. Kong B, Luyendyk JP, Tawfik O, Guo GL. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J Pharmacol Exp Ther 2009;328:116-22.
41. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009;49:S45-55.
42. Bonacini M. Pruritus in patients with chronic human immunodeficiency virus, hepatitis B and C virus infections. Dig Liver Dis 2000;32:621-5.
43. Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012;57:442-50.
44. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009;49:S156- 65.
45. Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM et al. Outcome of anti-HBe positive chronic hepatitis B in alphainterferon treated and untreated patients: a long term cohort study. J Hepatol 2002;36:263-70.
46. Singhal A, Kanagala R, Jalil S, Wright HI, Kohli V. Chronic HBV with pregnancy: reactivation flare causing fulminant hepatic failure. Ann Hepatol 2011;10:233-6.
47. Mason AL, Xu L, Guo L, Kuhns M, Perrillo RP. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 1998;27:1736-42.
48. Zhang NP, Reijnders JG, Perquin M, Hansen BE, Janssen HL. Frequency and clinical outcomes of flares related to nucleos(t)ide analogue therapy in patients with chronic hepatitis B. J Viral Hepat 2011;18:e252-7.
49. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182-8.
50. Mori N, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N et al. Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection. J Gastroenterol 2012;47:1022-9.
51. Wong VW, Wong GL, Yiu KK, Chim AM, Chu SH, Chan HY et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol 2011;54:236-42.
52. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-85.
53. Mason AL, Wick M, White HM, Benner KG, Lee RG, Regenstein F et al. Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis. Gastroenterology 1993;105:237-44.
54. Davies SE, Portmann BC, O'Grady JG, Aldis PM, Chaggar K, Alexander GJ et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991;13:150-7.
55. Ceballos-Viro J, Lopez-Picazo JM, Perez-Gracia JL, Sola JJ, Aisa G, Gil-Bazo I. Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer. World J Gastroenterol 2009;15:2290-2.
56. Jung S, Lee HC, Han JM, Lee YJ, Chung YH, Lee YS et al. Four cases of hepatitis B virus-related fibrosing cholestatic hepatitis treated with lamivudine. J Gastroenterol Hepatol 2002;17:345-50.
57. Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med 2011;364:2429-38.
58. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-6.
59. Fischer HP, Willsch E, Bierhoff E, Pfeifer U. Histopathologic findings in chronic hepatitis C. J Hepatol 1996;24:35-42.
60. Guido M, Mangia A, Faa G. Chronic viral hepatitis: the histology report. Dig Liver Dis 2011;43(Suppl 4):S331-43.
61. Kaji K, Nakanuma Y, Sasaki M, Unoura M, Kobayashi K, Nonomura A et al. Hepatitic bile duct injuries in chronic hepatitis C: histopathologic and immunohistochemical studies. Mod Pathol 1994;7:937-45.
62. Kumar KS, Saboorian MH, Lee WM. Cholestatic presentation of chronic hepatitis C: a clinical and histological study with a review of the literature. Dig Dis Sci 2001;46:2066-73.
63. Dries V, Odenthal M, Schirmacher P, Dienes HP. [Liver biopsy in chronic hepatitis C. Histopathology, molecular diagnostic analysis, and implications for therapeutic management]. Pathologe 2001;22:362-8.
64. Giannini E, Botta F, Fasoli A, Romagnoli P, Mastracci L, Ceppa P et al. Increased levels of gammaGT suggest the presence of bile duct lesions in patients with chronic hepatitis C: absence of influence of HCV genotype, HCV-RNA serum levels, and HGV infection on this histological damage. Dig Dis Sci 2001;46:524-9.
65. Giannini E, Ceppa P, Botta F, Fasoli A, Romagnoli P, Cresta E et al. Steatosis and bile duct damage in chronic hepatitis C: distribution and relationships in a group of Northern Italian patients. Liver 1999;19:432-7.
66. Silva IS, Ferraz ML, Perez RM, Lanzoni VP, Figueiredo VM, Silva AE. Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2004;19:314-8.
67. Benini F, Pigozzi MG, Baisini O, Romanini L, Ahmed H, Pozzi A et al. Increased serum gamma-glutamyl-transpeptidase concentration is associated with nonalcoholic steatosis and not with cholestasis in patients with chronic hepatitis C. J Gastroenterol Hepatol 2007;22:1621-6.
68. Lebovics E, Seif F, Kim D, Elhosseiny A, Dworkin BM, Casellas A et al. Pruritus in chronic hepatitis C: association with high serum bile acids, advanced pathology, and bile duct abnormalities. Dig Dis Sci 1997;42:1094-9.
69. Chia SC, Bergasa NV, Kleiner DE, Goodman Z, Hoofnagle JH, Di Bisceglie AM. Pruritus as a presenting symptom of chronic hepatitis C. Dig Dis Sci 1998;43:2177-83.
70. Jorquera F, Monte MJ, Guerra J, Sanchez-Campos S, Merayo JA, Olcoz JL et al. Usefulness of combined measurement of serum bile acids and ferritin as additional prognostic markers to predict failure to reach sustained response to antiviral treatment in chronic hepatitis C. J Gastroenterol Hepatol 2005;20:547-54.
71. Scholtes C, Diaz O, Icard V, Kaul A, Bartenschlager R, Lotteau V et al. Enhancement of genotype 1 hepatitis C virus replication by bile acids through FXR. J Hepatol 2008;48:192-9.
72. Chhatwal P, Bankwitz D, Gentzsch J, Frentzen A, Schult P, Lohmann V et al. Bile acids specifically increase hepatitis C virus RNA-replication. PLoS ONE 2012;7:e36029.
73. Chang KO, George DW. Bile acids promote the expression of hepatitis C virus in replicon-harboring cells. J Virol 2007;81:9633- 40.
74. Wagner M, Zollner G, Trauner M. Nuclear receptors in liver disease. Hepatology 2011;53:1023-34.
75. Iwata R, Stieger B, Mertens JC, Muller T, Baur K, Frei P et al. The role of bile acid retention and a common polymorphism in the ABCB11 gene as host factors affecting antiviral treatment response in chronic hepatitis C. J Viral Hepat 2011;18:768-78.
76. Iwata R, Baur K, Stieger B, Mertens JC, Daly AK, Frei P et al. A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease. Clin Sci (Lond) 2011;120:287-96.
77. Müllenbach R, Weber SN, Krawczyk M, Zimmer V, Sarrazin C, Lammert F et al. A frequent variant in the human bile salt export pump gene ABCB11 is associated with hepatitis C virus infection, but not liver stiffness in a German population. BMC Gastroenterol 2012;12:63.
78. Podevin P, Calmus Y, Bonnefis MT, Veyrunes C, Chereau C, Poupon R. Effect of cholestasis and bile acids on interferon-induced 2′,5′-adenylate synthetase and NK cell activities. Gastroenterology 1995;108:1192-8.
79. Narang TK, Ahrens W, Russo MW. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl 2010;16:1228-35.
80. McCaughan GW, Bowen DG. Pathogenesis of cholestatic hepatitis C. J Hepatol 2011;54:392-4.
81. Berenguer M, McCaughan G. Hepatitis C virus-associated cholestatic hepatitis: we cannot seem to agree on diagnostic criteria. Liver Transpl 2013;19:115-7.
82. Verna EC, Abdelmessih R, Salomao MA, Lefkowitch J, Moreira RK, Brown RS Jr. Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis. Liver Transpl 2013;19:78-88.
83. Fontana RJ, Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl 2012;18:1053-9.
84. Al Nahdi N, Ford JA, Greanya ED, Harrigan JA, Tse I, Steinbrecher UP et al. First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder. Ann Hepatol 2013;12:156-60.
85. Lammert F, Lorenzen J. Hepatitis, granulomatous. In: Lang F, editor. Encyclopedic Reference of Molecular Mechanisms of Disease. Berlin, Heidelberg: Springer; 2009: pp 818-21.
86. Matheus T, Munoz S. Granulomatous liver disease and cholestasis. Clin Liver Dis 2004;8:229-46, ix.
87. Rudzki C, Ishak KG, Zimmerman HJ. Chronic intrahepatic cholestasis of sarcoidosis. Am J Med 1975;59:373-87.
88. Moreno-Merlo F, Wanless IR, Shimamatsu K, Sherman M, Greig P, Chiasson D. The role of granulomatous phlebitis and thrombosis in the pathogenesis of cirrhosis and portal hypertension in sarcoidosis. Hepatology 1997;26:554-60.
89. Fischer HP, Zhou H. Nodular lesions of liver parenchyma caused by pathological vascularisation/perfusion. Pathologe 2006;27:273-83
90. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005;42:481-9
91. Andrade RJ, Lucena MI, Kaplowitz N, Garcia-Munoz B, Borraz Y, Pachkoria K et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 2006;44:1581-8
92. Bjornsson E, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol 2009;50:511-.
93. Russmann S, Jetter A, Kullak-Ublick GA. Pharmacogenetics of drug-induced liver injury. Hepatology 2010;52:748-61
94. Meier Y, Pauli-Magnus C, Zanger UM, Klein K, Schaeffeler E, Nussler AK et al. Interindividual variability of canalicular ATPbinding-cassette (ABC)-transporter expression in human liver. Hepatology 2006;44:62-74
95. Lang C, Meier Y, Stieger B, Beuers U, Lang T, Kerb R et al. Mutations and polymorphisms in the bile salt export pump and themultidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics 2007;17:47-60
96. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A et al. HLA-B*5701 genotype is a major determinant of druginduced liver injury due to flucloxacillin. Nat Genet 2009;41:816-9
97. Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010;42:711-4.
98. Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008;8:186-95
99. Weiler-Normann C, Schramm C. Drug induced liver injury and its relationship to autoimmune hepatitis. J Hepatol 2011;55: 747-9
100. Suzuki A, Brunt EM, Kleiner DE, Miquel R, Smyrk TC, Andrade RJ et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 2011;54:931-9
101. Desmet VJ. Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol 1997;26(Suppl 1):31-5
102. Reau NS, Jensen DM. Vanishing bile duct syndrome. Clin Liver Dis 2008;12:203-17, x
103. Ludwig J. Idiopathic adulthood ductopenia: an update. Mayo Clin Proc 1998;73:285-91
104. Read AE, Harrison CV, Sherlovk S. Chronic chlorpromazine jaundice: with particular reference to its relationship to primary biliary cirrhosis. Am J Med 1961;31:249-58
105. Degott C, Feldmann G, Larrey D, Durand-Schneider AM, Grange D, Machayekhi JP et al. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology 1992;15:244-51
106. Beuers U, Hohenester Sde Buy Wenniger LJ, Kremer AE, Jansen PL, Elferink RP. The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology 2010;52:1489-96
107. Müllenbach R, Lammert F. An update on genetic analysis of cholestatic liver diseases: digging deeper. Dig Dis 2011;29:72-7
108. Wendum D, Barbu V, Rosmorduc O, Arrive L, Flejou JF, Poupon R. Aspects of liver pathology in adult patients with MDR3/ABCB4 gene mutations. Virchows Arch 2012;460:291-8
109. Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy. World J Gastroenterol 2009;15:2049-66
110. Lammert F, Liebe R, Arrese M. Intrahepatic cholestasis of pregnancy: proposal for an updated classification based on genetics. In: Heaussinger D, Beuers U, Trauner M, editors. XXII International Bile Acid Meeting - Hepatic and Extrahepatic Targets of Bile Acid Signaling. Falk Symposium 184, Vienna; 2012: pp 83-7
111. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol 2012;56:671-85
112. Dhawan A, Taylor RM, Cheeseman P, De Silva P, Katsiyiannakis L, Mieli-Vergani G. Wilson's disease in children: 37-year experience and revised King's score for liver transplantation. Liver Transpl 2005;11:441-8
113. Huster D. Wilson disease. Best Pract Res Clin Gastroenterol 2010;24:531-9
114. Frezza M, Surrenti C, Manzillo G, Fiaccadori F, Bortolini M, Di Padova C. Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis. A double-blind, placebocontrolled study. Gastroenterology 1990;99:211-5
115. Mato JM, Camara J, Fernandez de Paz J, Caballeria L, Coll S, Caballero A et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999;30:1081-9
116. Pelletier G, Roulot D, Davion T, Masliah C, Causse X, Oberti F et al..A randomized controlled trial of ursodeoxycholic acid in patients with alcohol-induced cirrhosis and jaundice. Hepatology 2003;37:887-92
117. Beckett AG, Livingstone AV, Hill KR. Acute alcoholic hepatitis. Br Med J 1961;2:1113-9
118. Harinasuta U, Zimmerman HJ. Alcoholic Steatonecrosis. I. Relationship between severity of hepatic disease and presence of Mallory bodies in the liver. Gastroenterology 1971;60:1036-46
119. Galambos JT. Natural history of alcoholic hepatitis. 3. Histological changes. Gastroenterology 1972;63:1026-35
120. Birschbach HR, Harinasuta U, Zimmerman HJ. Alcoholic steatonecrosis. II. Prospective study of prevalence of Mallory bodies in biopsy speciemens and comparison of severity of hepatic disease in patients with and without this histological feature. Gastroenterology 1974;66:1195-202
121. Lilly LB. Drug-induced liver disease. In: Heathcote EJ, editor. Hepatology. Diagnosis and Clinical Management. Chichester: Wiley-Blackwell; 2012: pp 235-43
122. Mohi-ud-din R, Lewis JH. Drug- and chemical-induced cholestasis. Clin Liver Dis 2004;8:95-132, vii
123. Stickel F, Patsenker E, Schuppan D. Herbal hepatotoxicity. J Hepatol 2005;43:901-10
124. Abdalian R, Heathcote EJ. Sclerosing cholangitis: a focus on secondary causes. Hepatology 2006;44:1063-74